Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $133
Portfolio Pulse from jenniferd'souza@benzinga.com
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and raises the price target from $130 to $133.

June 07, 2023 | 10:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup maintains a Buy rating on Ultragenyx Pharmaceutical and raises the price target from $130 to $133.
The news of Citigroup maintaining a Buy rating and raising the price target for Ultragenyx Pharmaceutical (RARE) is positive for the stock. This indicates that the analyst believes the stock has potential for growth and is likely to perform well in the short term. The increased price target suggests an upward revision in the stock's valuation, which could attract more investors and drive the stock price higher.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100